Skip to content
OpenCapital
Get started

Spyre Therapeutics, Inc. SYRE Accrued contracted research and development costs

Other financials

Income statement

See full
Revenue-—
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-—
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept syre:AccruedContractedResearchAndDevelopmentCosts.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s accrued contracted research and development costs.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s accrued contracted research and development costs?
Spyre Therapeutics, Inc. (SYRE) reported accrued contracted research and development costs of $22.5M in Q1 2026.
How has Spyre Therapeutics, Inc.'s accrued contracted research and development costs changed year-over-year?
Spyre Therapeutics, Inc.'s accrued contracted research and development costs increased by 18.0% year-over-year, from $19.08M to $22.5M.
What is the long-term trend for Spyre Therapeutics, Inc.'s accrued contracted research and development costs?
Over 2 years (2023 to 2025), Spyre Therapeutics, Inc.'s accrued contracted research and development costs has grown at a 56.7% compound annual growth rate (CAGR), from $7.09M to $17.42M.